Search

Author/Creator Goetz, M P

2. 369TiPPATINA: A randomized, open label, phase III trial to evaluate the efficacy and safety of palbociclib + Anti-HER2 therapy + endocrine therapy (ET) vs. anti-HER2 therapy + ET after induction treatment for hormone receptor positive (HR+)/HER2-positive metastatic breast cancer (MBC). (23rd October 2018)

Authors:
Loibl, S; Metzger, O; Mandrekar, S J; Mundhenke, C; Seiler, S; Valagussa, P; DeMichele, A; Lim, E; Tripathy, D; Winer, E P; Huang, C; Carey, L; Francis, P; Miller, K D; Goetz, M P; Prat, A; Loi, S; Krop, I; Gianni, L; Ciruelos, E M
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer. (23rd March 2019)

Authors:
Veeraraghavan, J; Angelis, C De; Mao, R; Wang, T; Herrera, S; Pavlick, A C; Contreras, A; Nuciforo, P; Mayer, I A; Forero, A; Nanda, R; Goetz, M P; Chang, J C; Wolff, A C; Krop, I E; Fuqua, S A W; Prat, A; Hilsenbeck, S G; Weigelt, B; Reis-Filho, J S
Journal:
Annals of oncology
Issue:
Volume 30:Number 6(2019)
Page Start:
927
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. CYP2D6 Genotype and Adjuvant Tamoxifen: Meta‐Analysis of Heterogeneous Study Populations. Issue 2 (23rd September 2013)

Authors:
Province, M A; Goetz, M P; Brauch, H; Flockhart, D A; Hebert, J M; Whaley, R; Suman, V J; Schroth, W; Winter, S; Zembutsu, H; Mushiroda, T; Newman, W G; Lee, M‐T M; Ambrosone, C B; Beckmann, M W; Choi, J‐Y; Dieudonné, A‐S; Fasching, P A; Ferraldeschi, R; Gong, L
Journal:
Clinical pharmacology & therapeutics
Issue:
Volume 95:Issue 2(2014)
Page Start:
216
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗